ACAD
Price
$14.61
Change
+$0.26 (+1.81%)
Updated
Apr 23, 04:59 PM (EDT)
Capitalization
2.39B
19 days until earnings call
HRTX
Price
$2.20
Change
+$0.05 (+2.33%)
Updated
Apr 23, 04:59 PM (EDT)
Capitalization
335.13M
18 days until earnings call
Ad is loading...

ACAD vs HRTX

Header iconACAD vs HRTX Comparison
Open Charts ACAD vs HRTXBanner chart's image
ACADIA Pharmaceuticals
Price$14.61
Change+$0.26 (+1.81%)
Volume$35.13K
Capitalization2.39B
Heron Therapeutics
Price$2.20
Change+$0.05 (+2.33%)
Volume$7.83K
Capitalization335.13M
ACAD vs HRTX Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. HRTX commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and HRTX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ACAD: $14.62 vs. HRTX: $2.20)
Brand notoriety: ACAD and HRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 94% vs. HRTX: 74%
Market capitalization -- ACAD: $2.39B vs. HRTX: $335.13M
ACAD [@Biotechnology] is valued at $2.39B. HRTX’s [@Biotechnology] market capitalization is $335.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileHRTX’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • HRTX’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than HRTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 6 TA indicator(s) are bullish while HRTX’s TA Score has 7 bullish TA indicator(s).

  • ACAD’s TA Score: 6 bullish, 2 bearish.
  • HRTX’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, ACAD is a better buy in the short-term than HRTX.

Price Growth

ACAD (@Biotechnology) experienced а +0.34% price change this week, while HRTX (@Biotechnology) price change was +19.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

HRTX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.39B) has a higher market cap than HRTX($335M). HRTX YTD gains are higher at: 40.523 vs. ACAD (-21.798). ACAD has higher annual earnings (EBITDA): 100M vs. HRTX (-5.06M). ACAD has more cash in the bank: 756M vs. HRTX (59.3M). ACAD has less debt than HRTX: ACAD (52M) vs HRTX (178M). ACAD has higher revenues than HRTX: ACAD (958M) vs HRTX (144M).
ACADHRTXACAD / HRTX
Capitalization2.39B335M714%
EBITDA100M-5.06M-1,978%
Gain YTD-21.79840.523-54%
P/E Ratio10.55N/A-
Revenue958M144M665%
Total Cash756M59.3M1,275%
Total Debt52M178M29%
FUNDAMENTALS RATINGS
ACAD vs HRTX: Fundamental Ratings
ACAD
HRTX
OUTLOOK RATING
1..100
962
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
25100
PRICE GROWTH RATING
1..100
6257
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (58) in the Biotechnology industry is in the same range as HRTX (70). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HRTX (100). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's SMR Rating (25) in the Biotechnology industry is significantly better than the same rating for HRTX (100). This means that ACAD’s stock grew significantly faster than HRTX’s over the last 12 months.

HRTX's Price Growth Rating (57) in the Biotechnology industry is in the same range as ACAD (62). This means that HRTX’s stock grew similarly to ACAD’s over the last 12 months.

HRTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ACAD (100). This means that HRTX’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADHRTX
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SCWFX60.761.27
+2.13%
American Funds SMALLCAP World F1
GSISX29.23N/A
N/A
Goldman Sachs International Eq ESG Svc
FIKDX10.43N/A
N/A
Kempner Multi-Cap Deep Value Instl
HRSMX56.84N/A
N/A
Hood River Small-Cap Growth Instl
ASMZX12.13N/A
N/A
Alger Weatherbie Specialized Growth Z

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with RGNX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-0.21%
RGNX - ACAD
48%
Loosely correlated
+17.24%
HRTX - ACAD
44%
Loosely correlated
+11.40%
XNCR - ACAD
42%
Loosely correlated
+0.47%
RCKT - ACAD
41%
Loosely correlated
-2.79%
COGT - ACAD
41%
Loosely correlated
+0.93%
More

HRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with GSGTF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then GSGTF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRTX
1D Price
Change %
HRTX100%
+11.40%
GSGTF - HRTX
45%
Loosely correlated
N/A
AMRN - HRTX
44%
Loosely correlated
+9.53%
ACAD - HRTX
43%
Loosely correlated
-0.21%
SYRE - HRTX
39%
Loosely correlated
+2.87%
SNDX - HRTX
39%
Loosely correlated
+8.30%
More